Literature DB >> 12803879

Towards antibacterial strategies: studies on the mechanisms of interaction between antibacterial peptides and model membranes.

Andre Wiese1, Thomas Gutsmann, Ulrich Seydel.   

Abstract

Lipopolysaccharides (LPSs) play a dual role as inflammation-inducing and as membrane-forming molecules. The former role attracts significantly more attention from scientists, possibly because it is more closely related to sepsis and septic shock. This review aims to focus the reader's attention to the other role, the function of LPS as the major constituent of the outer layer of the outer membrane of Gram-negative bacteria, in particular those of enterobacterial strains. In this function, LPS is a necessary component of the cell envelope and guarantees survival of the bacterial organism. At the same time, it represents the first target for attacking molecules which may either be synthesized by the host's innate or adaptive immune system or administered to the human body. The interaction of these molecules with the outer membrane may not only directly cause the death of the bacterial organism, but may also lead to the release of LPS into the circulation. Here, we review membrane model systems and their application for the study of molecular mechanisms of interaction of peptides such as those of the human complement system, the bactericidal/permeability-increasing protein (BPI), cationic antibacterial peptide 18 kDa (CAP18) as an example of cathelicidins, defensins, and polymyxin B (PMB). Emphasis is on electrical measurements with a reconstitution system of the lipid matrix of the outer membrane which was established in the authors' laboratory as a planar asymmetric bilayer with one leaflet being composed solely of LPS and the other of the natural phospholipid mixture. The main conclusion, which can be drawn from these investigations, is that LPS and in general its negative charges are the dominant determinants for specific peptide-membrane interactions. However, the detailed mechanisms of interaction, which finally lead to bacterial killing, may involve further steps and differ for different antibacterial peptides.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12803879     DOI: 10.1179/096805103125001441

Source DB:  PubMed          Journal:  J Endotoxin Res        ISSN: 0968-0519


  17 in total

1.  Cyclic Tritrpticin Analogs with Distinct Biological Activities.

Authors:  Leonard T Nguyen; Johnny K Chau; Sebastian A J Zaat; Hans J Vogel
Journal:  Probiotics Antimicrob Proteins       Date:  2011-06       Impact factor: 4.609

2.  Interaction of antimicrobial peptide temporin L with lipopolysaccharide in vitro and in experimental rat models of septic shock caused by gram-negative bacteria.

Authors:  Andrea Giacometti; Oscar Cirioni; Roberto Ghiselli; Federico Mocchegiani; Fiorenza Orlando; Carmela Silvestri; Argante Bozzi; Antonio Di Giulio; Carla Luzi; Maria Luisa Mangoni; Donatella Barra; Vittorio Saba; Giorgio Scalise; Andrea C Rinaldi
Journal:  Antimicrob Agents Chemother       Date:  2006-07       Impact factor: 5.191

3.  The transcriptomic response of Acinetobacter baumannii to colistin and doripenem alone and in combination in an in vitro pharmacokinetics/pharmacodynamics model.

Authors:  Rebekah Henry; Bethany Crane; David Powell; Deanna Deveson Lucas; Zhifeng Li; Jesús Aranda; Paul Harrison; Roger L Nation; Ben Adler; Marina Harper; John D Boyce; Jian Li
Journal:  J Antimicrob Chemother       Date:  2015-01-14       Impact factor: 5.790

4.  Role of lipid A acylation in Yersinia enterocolitica virulence.

Authors:  Camino Pérez-Gutiérrez; Enrique Llobet; Catalina M Llompart; Mar Reinés; José A Bengoechea
Journal:  Infect Immun       Date:  2010-04-12       Impact factor: 3.441

5.  Modeling the electrostatic potential of asymmetric lipopolysaccharide membranes: the MEMPOT algorithm implemented in DelPhi.

Authors:  Roberta P Dias; Lin Lin; Thereza A Soares; Emil Alexov
Journal:  J Comput Chem       Date:  2014-05-06       Impact factor: 3.376

6.  Colistin resistance in Acinetobacter baumannii is mediated by complete loss of lipopolysaccharide production.

Authors:  Jennifer H Moffatt; Marina Harper; Paul Harrison; John D F Hale; Evgeny Vinogradov; Torsten Seemann; Rebekah Henry; Bethany Crane; Frank St Michael; Andrew D Cox; Ben Adler; Roger L Nation; Jian Li; John D Boyce
Journal:  Antimicrob Agents Chemother       Date:  2010-09-20       Impact factor: 5.191

7.  Kukoamine B, a novel dual inhibitor of LPS and CpG DNA, is a potential candidate for sepsis treatment.

Authors:  Xin Liu; Xinchuan Zheng; Ning Wang; Hongwei Cao; Yongling Lu; Yupeng Long; Kecen Zhao; Hong Zhou; Jiang Zheng
Journal:  Br J Pharmacol       Date:  2011-03       Impact factor: 8.739

Review 8.  Modulating LPS signal transduction at the LPS receptor complex with synthetic Lipid A analogues.

Authors:  Aileen F B White; Alexei V Demchenko
Journal:  Adv Carbohydr Chem Biochem       Date:  2014       Impact factor: 12.200

9.  Pharmacodynamic evaluation of suppression of in vitro resistance in Acinetobacter baumannii strains using polymyxin B-based combination therapy.

Authors:  Nayara Helisandra Fedrigo; Danielle Rosani Shinohara; Josmar Mazucheli; Sheila Alexandra Belini Nishiyama; Floristher Elaine Carrara-Marroni; Frederico Severino Martins; Peijuan Zhu; Mingming Yu; Sherwin Kenneth B Sy; Maria Cristina Bronharo Tognim
Journal:  Sci Rep       Date:  2021-05-31       Impact factor: 4.379

Review 10.  Biomimetic interfaces based on S-layer proteins, lipid membranes and functional biomolecules.

Authors:  Bernhard Schuster; Uwe B Sleytr
Journal:  J R Soc Interface       Date:  2014-05-08       Impact factor: 4.118

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.